Advanced Prostate Cancer VL

Clinical Genomic Risk Classification - Daniel Spratt

Details
A Conversation on Clinical Genomic Risk Classification - Alicia Morgans and Daniel Spratt (Length of Conversation: 25 min) Daniel Spratt, MD discusses the clinical challenges to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa) and how his team aimed to develop a novel clinical-genomic risk system that can...

PRONOUNCE Trial: Cardiovascular Outcomes in Prostate Cancer - Susan Slovin

Details
(Length of Conversation: 19 min) Alicia Morgans, MD, MPH and Susan Slovin, MD, PhD, discuss the PRONOUNCE trial , which looks at cardiovascular outcomes in patients with prostate cancer. Dr. Slovin highlights the importance of considering cardiovascular disease as it is the second most common cause of death in men with prostate cancer. Literature in the past 15-20 years on the use a GNRH agonists...

Role of MRI in Men on Active Surveillance - Laurence Klotz

Details
(Length of Discussion: 33 min) Tom Keane hosts a discussion with Laurence Klotz on the use of MRI in the detection of significant cancer and the possibility of MRI replacing biopsies in men on active surveillance. Dr. Klotz poses the question, can MRI replace biopsies in men on active surveillance? Through an overview of clinical trial data on 12 different published studies around this hot topic i...

Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? - Christopher Sweeney

Details
(Length of discussion - 26 minutes) Christopher Sweeney, MD presents on the Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? Dr. Sweeney addresses how we can cure more men from prostate cancer by taking a look at preventing relapse after definitive local therapy and radiation and hormonal therapy together vs radiation therapy alone. He reflects on the length of ti...

Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

Details
E. David Crawford hosts a discussion with Neal Shore and Jehonathan Pinthus on the adverse effects of androgen deprivation therapy (ADT). Viewers will gain knowledge on the optimal role of the antagonist vs agonist and a closer look at adverse effects of ADT and recommendations for patients undergoing ADT. The notion of sarcopenia and recommendations in fitness and strength training to reduce risk...

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?- Lorelei Mucci

Details
(Length of lecture ~ 19 minutes) Alicia Morgans hosts a discussion with Lorelei Mucci on her recently-published article in the Journal of Clinical Oncology that reviews a study on the association between statin use and the mortality rate in Danish patients who have prostate cancer. This study leverages the unique data sets available in Scandinavian countries where nationwide health registers can b...

What the Referring Clinician Needs to Know from Molecular Imaging in Prostate Cancer - Felix Feng

Details
(Length of lecture ~ 16 minutes) Dr. Feng provides a brief overview of prostate cancer management and how molecular imaging approaches can help guide the clinical management of prostate cancer, noting that imaging physicians need to educate their clinical colleagues about capabilities and limitations of these imaging studies. Additional content on molecular imaging ASCO 2017: How Advances in Molec...

Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing - Thomas Keane

Details
(Length of video ~17 min) Thomas Keane discusses strategies to mitigate side effects of androgen deprivation therapy (ADT) and the difference between intermittent versus continuous ADT. Dr. Keane focuses his lecture on the side effect of hot flashes while undergoing ADT therapy and recommendations for the management of hot flashes. Also, discussed is bone health and the acceleration of bone loss i...

Imaging in High Risk Prostate Cancer: Clinicians Perspective - Mark Frydenberg

Details
More from the 2017 APCCC (Advanced Prostate Cancer Consensus Conference): Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

High Risk Locally Advanced Prostate Cancer: What is the Optimal Surgery? - Nicolas Mottet

Details
(Length of Presentation: 8 min) Nicolas Mottet, MD presents on the optimal surgery for locally advanced and high-risk disease at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC). Laparoscopic and robot-assisted radical prostatectomy are used commonly. In experienced hands, the results of these approaches appear comparable to open surgical approaches. Nicolas also addresses nerve-spar...